To develop a vaccine for dengue, a chronic viral disease, Indiaâs leading pharmaceutical company Sun Pharma has signed a deal with the International Centre for Genetic Engineering and Biotechnology (ICGEB), Delhi.
It will be countryâs first vaccine (drug) for the treatment of dengue for safe, effective and affordable botanical drug Cipa, as it would be the first time a vaccine developed entirely in India for a vector-borne disease has been advanced for clinical development in India.
India has recorded one of the worst outbreaks this year with the union Health Ministry, noting 99,913 dengue cases and 220 deaths in 2015 and 33,310 cases and 20 deaths this year as of September 11.
According to the World Health Organisation, 390 million dengue infections are globally recorded annually, of which 96 million manifest clinically.
Dengue is transmitted by the Aedes Aegypti mosquito and can be caused by any of four closely-related viruses.
There was no proper treatment for dengue earlier expect fluids and paracetamol.
Because of the dengueâs provenance in at least 128 countries, several companies and international organisations have developed candidate vaccines that are in various stages of development and commercial release.
The most advanced is Dengvaxia, developed by French drug maker Sanofi and recommended for use since December last in Brazil, Mexico, Philippines and El Salvador for those 9-45 years old.